Pediatric macrophage activation syndrome: clinical features and outcomes across diverse etiologies.
- 8 July 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (7)
Abstract
To characterize clinical features and outcomes of pediatric macrophage activation syndrome (MAS) and examine associations with immune-regulatory genetic variation. This retrospective study included 120 children with MAS. Clinical, laboratory, and outcome data were analyzed. A subgroup underwent genetic testing for Hemophagocytic Lymphohistiocytosis (HLH)-related variants. Multivariable logistic regression identified factors associated with outcomes. Etiologies included multisystem inflammatory syndrome in children (MIS-C) (36.7%), systemic juvenile idiopathic arthritis (sJIA) (26.7%), infection-triggered MAS (23.3%), other rheumatologic diseases (10.8%), and lymphoma (2.5%). Intensive care unit (ICU) admission and acute organ failure occurred in 60% and 45%, and mortality was 17.5%. Compared with sJIA, non-sJIA had higher ICU admission (72.7% vs 25.0%, p= 0.02) and mortality (21.6% vs 6.3%, p= 0.04), whereas recurrence was more common in sJIA (28.1% vs 9.1%, p= 0.04). Stratified analyses (MIS-C, other MAS, and sJIA) showed higher ICU admission in MIS-C and other MAS, highest mortality in other MAS, and highest recurrence in sJIA, with rates of 77.3%, 68.2%, and 25.0% (p< 0.001), 6.8%, 36.4%, and 6.3% (p< 0.001), and 2.3%, 15.9%, and 28.1% (p= 0.01), respectively. Among tested patients, 22.4% carried HLH-related variants. Variant positivity was independently associated with higher ferritin, younger MAS onset, recurrence, acute organ dysfunction, and sJIA aetiology. Higher peak ferritin predicted mortality (OR 2.01) and reduced remission off therapy (OR 0.70), whereas sJIA aetiology was associated with lower mortality (OR 0.21). Pediatric MAS is etiologically heterogeneous, with inflammatory burden and organ dysfunction driving poor outcomes. Immune-regulatory variants are linked to severe or relapsing disease, supporting phenotype-guided stratification.Keywords
This publication has 31 references indexed in Scilit:
- A rare autoinflammatory syndrome associated with a C2orf69 frameshift mutation: a case reportImmunologic Research, 2025
- Early management of hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a systematic literature reviewEULAR Rheumatology Open, 2025
- Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic ArthritisArthritis & Rheumatology, 2024
- Severe adult hemophagocytic lymphohistiocytosis (HLHa) correlates with HLH-related gene variantsJournal of Allergy and Clinical Immunology, 2023
- Differences and similarities of multisystem inflammatory syndrome in children, Kawasaki disease and macrophage activating syndrome due to systemic juvenile idiopathic arthritis: a comparative studyRheumatology International, 2021
- 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative InitiativeArthritis & Rheumatology, 2016
- Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic SyndromeArthritis & Rheumatology, 2014
- Genetic Defects in Cytolysis in Macrophage Activation SyndromeCurrent Rheumatology Reports, 2014
- Whole‐Exome Sequencing Reveals Overlap Between Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis and Familial Hemophagocytic LymphohistiocytosisArthritis & Rheumatology, 2014
- HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatric Blood & Cancer, 2006